Polaryx Therapeutics (PLYX) Corporate presentation summary

Executive leadership and strategic focus

• Deep expertise in orphan pediatric diseases, with leadership experienced in successful biotech acquisitions.

• Focused on rare pediatric lysosomal storage disorders (LSDs) with disease-modifying drug candidates.

• Robust pipeline includes multiple regulatory designations and expedited clinical pathways.

Pipeline and clinical development

• Lead candidate PLX-200 is an oral small molecule targeting multiple LSDs, with IND-approved Phase 2 basket trial (SOTERIA) and pivotal trials cleared for CLN2 and CLN3.

• PLX-200 acts via PPARα activation, promoting lysosome biogenesis and anti-inflammatory gene expression.

• Additional candidates include PLX-300 (antioxidant/anti-inflammatory), PLX-100 (combination therapy), and PLX-400 (gene therapy).

Proof of concept and preclinical data

• PLX-200 demonstrated efficacy in animal models of CLN2, CLN3, Sandhoff, and Krabbe diseases, improving survival, motor function, and reducing pathological substrate accumulation.

• In vitro human data show upregulation of lysosomal biogenesis and TPP1 in patient fibroblasts.